NewsSource: EClinCloud Official Website Archive

EClinCloud Supports the Successful Third 2025 Meeting of the China Quality Association for Pharmaceuticals CRO Branch

1 min readEClinCloud Editorial Team
Archived article cover: EClinCloud supports the successful holding of the 2025 third meeting of the China Association for Pharmaceutical Quality CRO Branch


中国医药质量管理协会CRO分会2025第三次会议现场

 

On September 21, the third 2025 meeting of the Clinical Trial Contract Research Organization Branch of the China Quality Association for Pharmaceuticals (abbreviated as the "CRO Branch"), co-hosted by EClinCloud, was successfully held in Chengdu. Senior executives from companies including R&G PharmaStudies and Guoxin Pharmaceutical, along with 42 representatives from 31 member organizations, gathered to discuss industry trends.

 

 

Discussing AI and Clinical Research Development

This meeting focused on practical experience and application progress of AI in the industry. During the conference, Dr. Qin Long, Founder & CEO of EClinCloud, delivered a keynote presentation sharing the application progress of artificial intelligence across the entire pharmaceutical research and development chain.

 

CRO分会会议中的AI行业实践与应用分享  

 

Dr. Qin Long noted that the application of AI in pharmaceutical R&D has formed two major stages, "preclinical + clinical":

Preclinical stage: Significant results have already been achieved in areas such as target discovery and compound screening, and AI has become an important engine for accelerating drug R&D.

Clinical stage: Involving areas such as trial design, patient recruitment, and data management, it remains in an active exploratory phase and holds substantial potential.

Backed by leading technology, the EClinCloud intelligent AI platform achieves cost reduction and efficiency gains in areas such as text interpretation and protocol design. At the same time, he also noted that AI applications still face challenges such as data compliance and technical implementation, and that joint industry efforts are urgently needed to advance value realization.

 

CRO分会会议现场提问与交流  

At the meeting, other guests actively engaged in lively discussions on "AI Technology Development Pathways and Investment Strategies." Most representatives believed that amid the rapid iteration of AI technology, investment strategies should be formulated prudently based on practical realities to avoid blind development, while advocating collaboration and resource sharing to improve overall efficiency.